Buy Ozempic

Subcutaneously, into the stomach, thigh or shoulder, once a week at any time, regardless of food intake. Location of injection may change without dose correction.

Ozempiс must not be injected intravenously or intramuscularly!

 

Doses

 

The initial dose of Ozempic is 0.25 mg once a week.

After 4 weeks of use the dose should be increased to 0.5 mg once a week.

For further improvement of glycemic control after at least 4 weeks of use in a dose of 0.5 mg once a week the dose can be increased to 1 mg once a week. For weight loss, a dose of 0.5mg per week is usually sufficient.

 

The dose of Ozempic 0.25 mg is not therapeutic.

 

If the drug Ozempic is added to the previous therapy with metformin and/or thiazolidindione, the therapy with metformin and/or thiazolidindione can be continued in previous doses.

When adding the drug Ozempic to the ongoing therapy of sulfonylurea derivatives or insulin should be provided to reduce the dose of sulfonylurea derivatives or insulin to reduce the risk of hypoglycemia.

 

Application of Ozempic does not require self-control of blood glucose concentration. When using Ozempic in combination with sulfonylurea derivative or insulin, such self-control of blood glucose concentration may be required to correct the dose of sulfonylurea derivative or insulin.

1. Prepare a syringe pen with a new needle for use

 

• Remove the cap from the syringe pen.

 

• Take a new needle and remove the protective sticker. If the protective sticker is damaged, do not use the needle as sterility is not guaranteed in this case.

 

• Place the needle on the pen and rotate it to keep the needle tightly on the syringe.

 

• Remove the outer cap of the needle, but do not throw it away. You will need it after the injection is complete to safely remove the needle from the syringe pen.

 

• Remove and discard the inner needle cap.

 

Always use a new needle for each injection. Never use a needle if it is bent or damaged.

 

 

2. Check the supply of the drug

 

• Rotate the dose selector until the dose counter is equal to a symbol that checks medication supply.

 

• Hold the pen syringe with the needle up. Press and hold the Start button until the Dose counter returns to "0". "0" should stand opposite the pointer of the dose. A drop of solution should appear at the end of the needle.

 

Always make sure that there is a drop of solution at the end of the needle before using a new syringe pen for the first time. This guarantees the supply of the drug. If there is no drop of solution, the drug will not be injected, even if the dose counter will move. This may indicate that the needle is blocked or damaged. If intake is not checked before the first injection with each new syringe pen, the patient may not administer the required dose and the expected effect of Ozempic will not be achieved.

 

 

3. Dose Setting

 

• Rotate the dose selector until it shows the required dose.

 

• If the correct dose has not been selected, rotate the dose selector forward or backward until the correct dose is set.

 

• You should not count the clicks of a syringe pen.

 

 

4. Ozempic injection

 

• Inject a needle under the skin, using an injection technique recommended by a doctor or nurse.

 

• Make sure that the dose counter is in sight of the person administering the injection. Do not touch the dose counter with your fingers - this may interrupt the injection.

 

• Press the start button all the way down and hold it in this position until the dose counter shows "0". The "0" must be exactly opposite the dose indicator. At the same time, the patient may hear or feel a click.

 

• Hold the needle under the skin, after the dose counter returned to "0" and slowly count to 6.

 

• Remove the needle from under the skin. If there is blood at the injection site, you should lightly press a cotton swab to the injection site. Do not massage the place of injection. After the injection, the patient may see a drop of solution on the end of the needle. This is normal and does not affect the dose of the drug that was injected.

 

 

5. After the completion of the injection.

 

• By placing the outer needle cap on a flat surface, insert the needle end into the cap without touching it or the needle.

 

• When the needle enters the cap, carefully put the outer cap on the needle.

 

• Unscrew the needle and throw it away, following the safety precautions.

 

After each use, put a cap on the syringe pen to protect the solution contained in it from light

In case of missed dose, Ozempiс should be administered as soon as possible within 5 days from the scheduled dose.

If the missing time is more than 5 days, the missed dose should not be administered. The next dose of Ozempiс should be given on a normal scheduled day.

In each case, patients can resume their usual one-time weekly schedule of administration.

There were no particular complications with Ozempic overdose. All patients recovered from the overdose with Ozempic.

 

Symptoms: nausea.

 

Treatment: There is no specific antidote for Ozempic overdose. In case of overdose it is recommended to perform the appropriate symptomatic therapy.

Ozempic should not be taken by patients with:

 

• hypersensitivity to semaglutide or any of the auxiliary substances of the preparation;

 

• medullary thyroid cancer in the history, including family history;

 

• multiple endocrine neoplasia type 2;

 

• type 1 diabetes mellitus;

 

• diabetic ketoacidosis.

 

 

Use of Ozempic is contraindicated in the following groups of patients and in the following states/diseases due to lack of data on efficacy and safety or limited experience in use:

 

• pregnancy and the period of breastfeeding;

 

• age under 18 years;

 

• severe liver insufficiency;

 

• terminal stage of renal insufficiency (creatinine Cl <15 ml/min);

 

• Chronic Heart Failure (CHF), functional class IV (according to the NYHA classification).

 

 

Caution: Ozempic is recommended to be used with caution for patients with renal failure and patients with pancreatitis in the history.

Side effects of Ozempic are classified by system-organ class according to MedDRA, with the frequency of their occurrence indicated according to who recommendations: very often (≥ 1/10); often (≥1/100 to < 1/10); not often (≥ 1/1000 to < 1/100); rarely (≥ 1/10 000 to < 1/1000) and very rarely (< 1/10 000).

 

Immune System: 

Rarely: Anaphylactic reactions.

 

Metabolism and nutrition

Very often: Hypoglycemia when used together with insulin and sulfonilic urea derivatives.

Often: Reduced appetite, Hypoglycemia when used together with other oral hypoglycemic medicines.

 

Nervous system

Often: Dizziness.

Not often: Disgevsia.

 

Organ of vision

Often: Diabetic retinopathy complications.

 

Heart

Not often: Increased Heart rate.

 

Gastrointestinal tract

Very often: Nausea, diarrhea.

Often: Vomiting, abdominal pain, bloating, constipation, dyspepsia, gastritis, gastroesophageal reflux disease, belching, flatulence.

 

Liver and biliary tract

Often: Cholelithiasis.

 

General disorders and disorders at the injection site

Often: Tiredness.

Not often: Reactions at the injection site (rash, redness.

 

Laboratory and instrumental data

Often: Increase in lipase activity, increase in amylase activity, decrease in body weight.

 

 

The most commonly reported undesired reactions were gastrointestinal abnormalities, including nausea, diarrhea and vomiting. In general, these reactions were mild to moderate severity and short-term.

In 1 ml of the preparation is contained:

 

active ingredient: semaglutide 1.34 mg;

 

auxiliary substances: hydrophosphate dihydrate dynatrium, propylene glycol, phenol, hydrochloric acid (for pH correction), sodium hydroxide (for pH correction), water for injection.

 

For Ozempic 1 mg/dose syringe pen:

 

One 1,5 ml pre-filled pen syringe contains 2 mg of semaglutide.

One 3 ml pre-filled pen syringe contains 4 mg of semaglutide.

Semaglutide, a glucagone-like peptide-1 receptor agonist (GLP-1), administered daily in a single subcutaneous dose of 0.4 mg for 52 weeks, resulted in weight loss of 13.8% (p<0.0001). In the control group placebo, the weight reduction was 2.3%.

 

Phase II clinical trials that tested semaglutide versus placebo and 3 mg Victoza/Saxenda (liraglutide) among obese patients without a diagnosis of diabetes revealed that 83% of patients in the group lost at least 5% of their weight, while in placebo and liraglutide groups this was fair for 23% and 66% of participants. Weight loss by 10% and more was recorded for 65%, 10% and 34% of the subjects respectively. 

This means that Ozempic is more effective for weight loss than the proven Saxenda.

For weight loss Ozempic should be taken daily in a single subcutaneous dose of 0.4 mg for 52 weeks.

You can buy Ozempic from our website absolutely legally.

Delivery is carried out to all countries in the world, which do not have an official ban on receiving and sending mail (mainly island countries).

We guarantee that you will receive your parcel with Ozempic without any problems at customs (we have our own delivery channels to countries with strict customs).

We guarantee a refund if your package has not been delivered to you for any reason, according to PayPal protection policy.

Due to Quarantine, delivery time may increase slightly, but still delivery remains within reasonable limits and does not exceed the delivery time during Christmas sales.

There is no prescription required!

You can legally buy Ozempic on our website without prescription!